Cargando…

Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy

BACKGROUND: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. Predicting factors for favorable outcomes are still unknown. We aimed to investigate whether histological vascular lesions at the time of conversion might...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Sáez, María José, Yu, Bryant, Uffing, Audrey, Murakami, Naoka, Borges, Thiago J, Azzi, Jamil, El Haji, Sandra, Gabardi, Steve, Riella, Leonardo V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Transplant Immune Suppression
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671390/ https://www.ncbi.nlm.nih.gov/pubmed/31384452 http://dx.doi.org/10.1093/ckj/sfy115

Ejemplares similares

Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis
por: Ali, Hatem, et al.
Publicado: (2019)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation
por: Uffing, Audrey, et al.
Publicado: (2019)

A Mixed-chimerism Protocol Utilizing Thymoglobulin and Belatacept Did Not Induce Lung Allograft Tolerance, Despite Previous Success in Renal Allotransplantation
por: Sommer, Wiebke, et al.
Publicado: (2021)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects
por: Abramowicz, Daniel, et al.
Publicado: (2008)

Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
por: Tedesco-Silva, Helio, et al.
Publicado: (2016)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
por: Johnson, Aileen C., et al.
Publicado: (2023)

Efficacy of Prolonged-release Tacrolimus After Conversion From Immediate-release Tacrolimus in Kidney Transplantation: A Retrospective Analysis of Long-term Outcomes From the ADMIRAD Study
por: Kuypers, Dirk, et al.
Publicado: (2023)

Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study
por: Wali, Ravinder K., et al.
Publicado: (2016)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

Factors Associated With Reduced Anti-SARS-CoV-2 Antibody Responses After mRNA Vaccination in Kidney Transplant Recipients on Belatacept
por: Morena, Leela, et al.
Publicado: (2022)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Early Versus Late Conversion From Immediate to Prolonged-Release Tacrolimus After Renal Transplantation: Clinical Effects and Treatment Costs
por: Mendonça, Luís, et al.
Publicado: (2018)

Acute kidney injury in an infant of a kidney allograft recipient
por: Aktürk, Serkan, et al.
Publicado: (2019)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient
por: Klintmalm, Göran B., et al.
Publicado: (2022)

Influence of broader geographic allograft sharing on outcomes and cost in smaller lung transplant centers
por: Haywood, Nathan, et al.
Publicado: (2020)

Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab
por: Merhi, Basma, et al.
Publicado: (2017)

Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes
por: Cohen, Jordana B., et al.
Publicado: (2017)

Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study
por: Osmanodja, Bilgin, et al.
Publicado: (2023)

Tacrolimus-Induced Optic Neuropathy After Multivisceral Transplantation
por: Canovai, Emilio, et al.
Publicado: (2019)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
por: Hashmi, Hamza, et al.
Publicado: (2020)

Abstract: Belatacept and Rapamycin with Short-Term Use of Tacrolimus Delay Allograft Rejection in a Novel, Large Animal Vascularized Composite Allotransplantation Model
por: Elgendy, Tarek, et al.
Publicado: (2018)

The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease
por: Pang, Yifan, et al.
Publicado: (2022)

EXCELLENT ALLOGRAFT RECOVERY DESPITE PROLONGED SARS-COV-2 SHEDDING AFTER REDUCTION OF IMMUNOSUPPRESSION IN LUNG TRANSPLANT RECIPIENT
por: RAZIA, DEEPIKA, et al.
Publicado: (2021)

The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function
por: Mahaparn, Irisa, et al.
Publicado: (2023)

Tacrolimus-Induced Hyponatremia in Lung Transplant Recipients: A Case Series
por: Banks, Paul N., et al.
Publicado: (2018)

Effect of Combined Gluten-Free, Dairy-Free Diet in Children With Steroid-Resistant Nephrotic Syndrome: An Open Pilot Trial
por: Leon, Juliette, et al.
Publicado: (2018)

Pulmonary Allograft Versus Host Disease
por: Dai, David W., et al.
Publicado: (2017)

Procurement Biopsy Findings Versus Kidney Donor Risk Index for Predicting Renal Allograft Survival
por: Hall, Isaac E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f4mkjeqqsoslpn1qmakcv81ek1